Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

This study has been terminated.
(Administratively complete.)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: February 14, 2002
Last updated: January 15, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)